Fundamental Analysis (Long term)

MOLBIO DIAGNOSTICS | FROM A DIAGNOSTICS COMPANY TO A GLOBAL MOLECULAR-TESTING PLATFORM BUSINESS ANATOMY — THE TRUENAT “RAZOR & BLADE” MODEL - Molbio's business is built around its Truenat portable, battery-operated real-time PCR platform. - The model has two interconnected layers: - Truenat devices = “Razor” - Micro-PCR chips + reagent test kits = “Blades” - Once a Truenat machine is installed at a hospital, health centre or government facility, it creates a recurring requirement for consumable test kits. - This creates the potential for a razor-and-blade revenue model, where the installed hardware base supports recurring consumables revenue. - The strategic opportunity is therefore not simply selling diagnostic machines, but continuously increasing the installed base and utilisation of that installed base. BALANCE SHEET — ASSET STRUCTURE - Net fixed assets are approximately ₹257 Cr as of March 2026. - Current assets are approximately ₹1,003 Cr. - Manufacturing and R&D infrastructure is concentrated primarily around Goa and Bengaluru. - These facilities support manufacturing of Truenat devices, chips and associated diagnostic products. - Current assets are heavily influenced by inventory and trade receivables, reflecting the working-capital requirements of government and B2B contracts. - The balance sheet therefore reflects a business that requires meaningful upfront working capital to support its growth. WORKING CAPITAL — IMPROVING BUT STILL HIGH - Net working capital is approximately ₹622 Cr. - Cash Conversion Cycle is around 112 days. - This means capital remains tied up in inventory and receivables for roughly 3.5 months before being converted back into cash. - The positive development is that the cycle has improved significantly from the historical 3-year median of approximately 155 days. - Continued improvement in working-capital efficiency could become an important source of cash-flow leverage. ASSET PRODUCTIVITY & MARGINS - FY26 operating revenue was approximately ₹1,445.6 Cr against a total asset base of around ₹1,692 Cr. - This implies an asset-turnover ratio of approximately 0.85x. - Operating profit margin has stabilised around 22–25%. - FY26 operating profit was approximately ₹320 Cr. - PAT margin is around 11.3%. - The business therefore combines meaningful gross margins with a relatively asset-light scaling opportunity once the installed Truenat infrastructure is established. CAPACITY — ROOM FOR ORGANIC SCALING - Current manufacturing utilisation is around 50%. - This is strategically important because substantial growth can potentially be accommodated without immediately building equivalent new manufacturing capacity. - Management therefore expects future scaling to require relatively limited near-term factory expansion. - Incremental cash generation can instead be directed toward R&D, customer acquisition and global expansion. IPO CAPITAL — R&D + AUTOMATION - Molbio raised approximately ₹200 Cr of fresh capital through its IPO in August 2026. - Proposed utilisation includes: - ₹105 Cr: Integrated R&D facility and Center of Excellence in Bengaluru - ₹72 Cr: Manufacturing automation in Goa - The allocation indicates that management is prioritising technology capability and manufacturing efficiency rather than simply adding large amounts of physical capacity. - This is consistent with the strategy of scaling the existing platform while improving long-term product development capabilities. REVENUE MODEL — WHY GROWTH CAN BECOME NON-LINEAR - Molbio's revenue is not expected to move in a perfectly linear quarterly pattern. - A significant portion of domestic demand comes from institutional and public-health procurement, including government tenders. - Tender timing and public-health budget deployment can therefore create quarterly volatility. - However, delayed orders are not necessarily lost orders. - Q1 FY27 provides an example: approximately ₹57 Detail Analysis of Molbio Diagnostics ⤵️ https://t.me/fundamental3/59025

GMM Pfaudler , mapping the capex of Customer Industries , again not an exhaustive list , but something to keep read on source: incred research

INDEGENE | FROM LIFE-SCIENCES SERVICES TO ENTERPRISE GENERATIVE AI CORE BUSINESS — STRONG FOUNDATION - Indegene is already a major technology and services partner to global pharma and healthcare companies. - Quarterly revenue recently reached approximately ₹1,063 Cr | ~40% YoY growth. - Customer base includes 105+ major global healthcare and pharmaceutical companies. - The existing business provides a strong foundation in medical content, commercialisation, clinical data, compliance and healthcare workflows. - The important strategic question is whether this services-led foundation can evolve into a higher-value, software-led platform business. GENERATIVE AI — THE NEW GROWTH ENGINE - Indegene is seeing meaningful early traction in Enterprise Generative AI. - More than 50 AI pilot projects are currently being tested by clients. - The company is using its multi-million-dollar Tectonic AI software engine to build and deploy GenAI solutions. - Current AI products include: - Smart content applications - Automated medical writing - Clinical data tools - The opportunity is potentially much larger than simply using AI internally to improve productivity. - The strategic goal is to turn AI capabilities into repeatable, scalable software products for life-sciences customers. MICROSOFT PARTNERSHIP — AI + DOMAIN EXPERTISE - Indegene has partnered with Microsoft to build and launch AI solutions specifically for the highly regulated healthcare and pharmaceutical industry. - The combination is important because enterprise healthcare AI requires more than generic AI models. - Customers need security, compliance, workflow integration, domain accuracy and regulatory controls. - Indegene's life-sciences expertise can potentially become the layer that makes enterprise AI usable within these highly regulated environments. WHY LIFE-SCIENCES DOMAIN KNOWLEDGE MATTERS - Healthcare AI operates within a much more complex environment than general enterprise applications. - Indegene already understands: - Medical and regulatory compliance - Drug safety and pharmacovigilance data - Clinical-trial processes - Scientific and medical literature - Doctor and hospital workflows - Pharma commercialisation processes - These capabilities could become an important barrier to entry for generic AI companies attempting to enter healthcare. - The bigger opportunity is potentially an end-to-end AI layer for life sciences, rather than isolated AI applications. POTENTIAL PLATFORM OPPORTUNITY - The long-term opportunity could be to combine multiple workflows into a single AI-enabled healthcare operating platform. - Potential building blocks include: Medical content → Medical writing → Clinical data → Drug safety → Compliance → Commercial workflows - If these applications become interconnected, Indegene could potentially move from selling individual services toward providing AI-powered workflow infrastructure. - That could increase scalability, recurring revenue potential and customer stickiness. MARGINS — POTENTIAL AI OPERATING LEVERAGE - Management expects profit margins to recover toward approximately 19–20%. - A successful transition toward software and AI products could create additional operating leverage over time. - The key attraction is that software revenue can potentially scale faster than people-driven services without requiring proportional increases in employee costs. - However, this margin expansion needs to be demonstrated through actual product adoption and revenue mix, not merely AI pilot activity. AI PILOTS — THE CRITICAL CONVERSION TEST - The 50+ AI pilots are an important early indicator of customer interest. - But pilots alone do not establish a scalable AI business. - The critical progression is: Pilot → Production deployment → Paid contract → Recurring usage → Multi-product expansion - The biggest question is whether Indegene can convert its current AI experimentation into large, repeatable and recurring software revenue. - Pilot-to-production conversion should therefore be one of the most important metrics to track. CORE BUSINESS + AI — THE STRATEGIC ADVANTAGE - Indegene is not building an AI business completely from scratch. - It already has: - Deep life-sciences domain knowledge - Large global pharma relationships - Healthcare data and workflows - Regulatory expertise - Existing enterprise distribution - This creates a potential advantage because AI products can be introduced to existing customers rather than requiring an entirely new customer-acquisition engine. - The installed customer base could therefore become an important distribution channel for future AI products. THE BUSINESS MODEL TRANSITION - The existing business is predominantly services and consulting-led. - The emerging opportunity is to increase the contribution from software, AI products and reusable technology platforms. - This creates the possibility of a structural business-model transition: Human-driven services → AI-assisted services → AI-enabled workflows → Scalable enterprise software - The further Indegene moves along this spectrum, the greater the potential for scalability and margin expansion. WHAT TO WATCH NEXT - Conversion of the 50+ AI pilots into commercial production deployments. - Size and duration of AI contracts. - Growth in recurring/software revenue. - Contribution of Tectonic AI and other AI products to total revenue. - Whether AI adoption expands across multiple workflows within existing pharma customers. - Progress of the Microsoft partnership and resulting commercial deployments. - Recovery of margins toward the 19–20% range. - Whether AI revenue grows fast enough to materially change the company's overall revenue mix. KEY RISKS - AI pilots may not convert into large commercial contracts. - Enterprise pharma customers may adopt GenAI more slowly than expected because of regulatory, privacy and compliance constraints. - Generic AI platforms could increasingly compete in healthcare workflows. - Significant investment may be required before AI products reach meaningful scale. - The core services business could remain the dominant revenue contributor for longer than expected. - Margin expansion may not materialise if AI revenue remains small relative to employee-driven services. CRUX - Indegene's existing business provides the domain moat, customer relationships and healthcare infrastructure. - Generative AI provides the potential scalability and margin-expansion opportunity. - The company therefore has an interesting combination: 105+ global healthcare customers + deep life-sciences expertise + 50+ GenAI pilots + Tectonic AI + Microsoft partnership. - But the AI opportunity is still in the validation phase. - The central question is not whether pharma companies are interested in GenAI. - The real question is: Can Indegene convert 50+ pilots into large, recurring, high-margin software revenue? KEY TAKEAWAY - Indegene could be entering an important transition from a life-sciences services company toward an AI-enabled healthcare technology platform. - The existing business gives it a meaningful starting advantage because it already understands the data, regulations, workflows and customers that healthcare AI needs. - If AI products achieve strong production adoption, the company could potentially experience a shift toward higher scalability, recurring revenue and stronger margins. - For now, the 50+ AI pilots are the leading indicator. - The next major proof point is pilot → production → recurring revenue. - The AI opportunity is exciting; the conversion of that opportunity into financial outcomes is the real test. DISCLAIMER - Educational purposes only. - Not a buy/sell recommendation. Detail Analysis of Molbio Diagnostics ⤵️ https://t.me/fundamental3/59025

KROSS LTD | INTEGRATED AUTO-COMPONENT PLAY WITH A FORENSIC WATCHLIST BUSINESS MODEL — BACKWARD INTEGRATION - Kross is an integrated auto-component manufacturer supplying: - Trailer axles & suspension assemblies - Forged, cast and machined components - M&HCV components - Tractor and off-highway components - The key differentiator is backward integration across design and component manufacturing. - The business is therefore positioned beyond simple component machining, with greater control over the manufacturing chain. FINANCIAL TRAJECTORY — STEADY ACCELERATION - Revenue increased from ₹570 Cr in FY24 → ₹620 Cr in FY25 → ₹673 Cr in FY26. - FY26 PAT stood at approximately ₹55.2 Cr | +15% YoY. - Q1 FY27 revenue reached ₹184.34 Cr | +32.3% YoY. - Q1 FY27 PAT was ₹13.31 Cr | +24.4% YoY. - The growth rate in Q1 FY27 suggests that the business is entering a stronger operating phase. QUARTERLY MOMENTUM - Revenue trajectory: - Q2 FY25: ₹139 Cr - Q3 FY25: ₹150 Cr - Q4 FY25: ₹185 Cr - Q1 FY26: ₹139 Cr - Q2 FY26: ₹131 Cr - Q3 FY26: ₹177 Cr - Q4 FY26: ₹225 Cr - Q1 FY27: ₹184 Cr - The business has clearly accelerated from the weaker Q1/Q2 FY26 base. - The key question is whether the higher revenue run-rate can become sustainable rather than merely cyclical. BALANCE SHEET — GENERALLY CLEAN - Debt-to-equity is approximately 0.26x. - Promoter holding is around 68.57%. - Promoter pledge: 0%. - Credit rating: IND A / Stable. - No major promoter loans or guarantees were identified. - No subsidiaries, associates or JVs. - Auditor opinion is unmodified. - Overall, the balance sheet and governance checks do not currently indicate a major structural red flag. WORKING CAPITAL — FIRST YELLOW FLAG - Working-capital days have increased from approximately 87 → 124 days. - Receivables and inventory have both been rising. - FY26 PAT was approximately ₹55.2 Cr, while CFO was only around ₹18 Cr. - This creates an important cash-conversion gap. - Profit growth therefore needs to increasingly translate into operating cash flow. - The critical metric to watch is whether working-capital days begin to normalise as revenue scales. ₹63.6 Cr PREFERENTIAL ISSUE — EXPANSION CAPITAL - On 31 August 2026, Kross proposed a preferential issue of approximately ₹63.6 Cr. - Structure: - ₹31.8 Cr equity shares - ₹31.8 Cr convertible warrants - Issue price: ₹212/share. - The capital is primarily intended for business expansion rather than balance-sheet repair. - This makes capital allocation and post-investment returns particularly important. USE OF FUNDS — PRODUCTIVE CAPEX FOCUS - ₹15 Cr: Shaft-component capacity - ₹15 Cr: CDT forward integration - ₹13 Cr: Robotic automation - ₹5 Cr: Administrative office - ₹10.6 Cr: Working capital - ₹5 Cr: General corporate purposes - Approximately 68% of the proposed funds are directed toward productive capex. - The expansion therefore has the potential to increase capacity, integration and manufacturing automation. PREFERENTIAL ALLOTMENT — FORENSIC WATCHPOINT - The proposed equity allottees are officially classified as non-promoters: - Gauravrajsingh V. Rathore - Dhruv Agarwal - Saroj V. Rathore - Richa Gauravrajsingh Rathore - Promoter warrants are proposed for: - Sumeet Rai - Kunal Rai - The allottee structure warrants additional scrutiny because the capital is being raised from a defined group of investors. INVESTOR-NETWORK CONNECTION — IMPORTANT DISTINCTION - Gauravrajsingh Rathore and Dhruv Agarwal have a common directorship connection through Grey Eminence Capital Funds Pvt Ltd. - Some of these investors also appeared in earlier preferential-allotment activity in AEIM. - This establishes an investment-network connection. - It does not by itself establish promoter linkage, related-party status or wrongdoing. - The appropriate approach is therefore continued verification rather than treating the connection as a red flag by itself. FORENSIC CHECKLIST — POSITIVE SIGNALS - 0% promoter pledge. - Unmodified auditor opinion. - No major contingent-liability trigger identified. - No material promoter loans/guarantees identified. - Related-party transactions are disclosed. - No fraud finding identified. - These checks provide a relatively clean baseline for deeper monitoring. FORENSIC WATCHLIST - Preferential-allotment execution: verify final allotment, approvals and fund deployment. - Allottee independence: continue checking relationships and common directorships. - Working capital: receivables, inventory and cash conversion require improvement. - Capacity execution: proposed capex needs to translate into productive capacity and incremental revenue. - Capital productivity: new capital should ultimately produce higher PAT, CFO and ROCE. FMQC SCORE — 92/100 - Business Quality: 16/20 - Financial Performance: 13/15 - Moat: 13/15 - Growth: 13/15 - Management/Governance: 12/15 - Cash Flow/Balance Sheet: 8/10 - Valuation + Peers: 9/10 - Forensic Quality: 8/10 - Overall: FMQC QUALIFIED THE CAPITAL-ALLOCATION TEST - Kross is now moving from a relatively straightforward auto-component growth story toward a more integrated manufacturing platform. - The preferential capital creates an important test of management's capital-allocation discipline. - The desired progression is: New capital → Capacity/automation → Higher volumes → Higher PAT → Stronger CFO → Higher ROCE - At the same time, working-capital days should ideally move in the opposite direction: 124 days → normalisation/improvement. - If both occur, the expansion thesis becomes materially stronger. KEY MILESTONES TO WATCH - Conversion of Q1 FY27 growth into sustained quarterly revenue. - Progress of shaft-component capacity expansion. - Execution of CDT forward integration. - Benefits from robotic automation. - Preferential issue completion and actual deployment of funds. - Working-capital days and cash conversion. - Incremental CFO versus PAT. - Incremental ROCE generated from the new capital. - Whether the higher capacity translates into sustainable margin and earnings growth. CRUX - Kross combines a growing auto-component business + backward integration + low leverage + high promoter ownership + zero promoter pledge. - The financial trajectory is encouraging, with FY26 revenue at ₹673 Cr and Q1 FY27 revenue growth of 32.3%. - But the forensic picture is not completely clean-cut because working-capital intensity has increased and the preferential allotment deserves continued scrutiny. - The new ₹63.6 Cr capital raise is therefore the next major test. - The question is not simply whether Kross can grow revenue. - The real question is: Can the company convert incremental capital into incremental PAT + CFO + ROCE while simultaneously improving working-capital efficiency? KEY TAKEAWAY - Kross is attempting to evolve from an auto-component manufacturer into a more integrated, automated and higher-value manufacturing platform. - The combination of backward integration + strong promoter holding + low leverage + zero pledge + improving revenue momentum provides a solid base. - The two areas requiring the most attention are cash conversion and capital-allocation discipline. - The preferential issue could become a meaningful growth catalyst if the proceeds generate strong incremental returns. - Conversely, if working-capital days remain elevated and new capacity fails to generate adequate cash returns, the expansion thesis becomes harder to justify. - The next phase is not about proving demand. It is about proving capital productivity. FMQC CONCLUSION - 92/100 | FMQC QUALIFIED - Current setup: Positive business trajectory + clean balance sheet + expansion opportunity + forensic watchpoints. - The score can strengthen if CFO, ROCE and working-capital efficiency improve alongside capacity utilisation. - It can weaken if capital deployment, allottee structure or cash conversion deteriorates. DISCLAIMER - For research and educational purposes only. - Not a buy/sell recommendation.

KROSS LTD DETAIL ANALYSIS 🧵

WATER INFRA – FY27 GROWTH OUTLOOK Growth Outlook - Wabag, Ion Exchange: 15–20% growth - EMS: 18–30% growth FY27 Revenue Targets - Jash Engineering: ₹875 Cr - Denta Water: ₹375–400 Cr - Felix Industries: ₹180–200 Cr Long-Term Target - Jash targets ₹1,500 Cr by FY31 Key Takeaway - Water infrastructure shows strong growth potential - Multiple players expect double-digit growth - Jash offers significant long-term scale-up opportunity

RACL GEARTECH | TWO CAPEX CLOCKS — QUALIFICATION VS COMMERCIAL ALLOCATION TWO DIFFERENT CAPEX LOGICS - RACL is effectively running two different capex clocks depending on the customer programme. - Sole-source export programmes: long qualification cycles and long product lives can justify dedicated capacity before full volumes arrive. - Multi-source domestic programmes: management prefers to see stable commercial allocation first before committing significant capital. - This disciplined approach helps avoid investing ahead of demand. BMW — QUALIFICATION MILESTONE - BMW has reached Level-1 PPAP, with conditional and pilot supplies already underway. - Final BMW sign-off visit is scheduled for 24 October. - The October sign-off would be an important validation that RACL has cleared the technical qualification hurdle. - BMW therefore represents a programme where qualification can precede full-scale volume and capacity investment. ROYAL ENFIELD — COMMERCIAL ALLOCATION MILESTONE - Royal Enfield is currently running at 7,500–8,000 sets/month. - Nomination is approximately 10,000 sets/month. - The key question is not merely whether RACL can produce the parts, but whether the 10,000-set allocation becomes stable and repeatable. - This is the type of visibility management wants before making aggressive capacity investments in a multi-supplier environment. TVS — SOLE-SUPPLIER POSITION - RACL is the sole supplier for the complete gear train above 350cc for TVS. - Sole-source relationships provide stronger visibility and can support earlier dedicated capacity creation. - This highlights the difference between strategic sole-source programmes and competitive multi-supplier programmes. ZF — LONG-DATED EV OPPORTUNITY - ZF electric-steering revenue is expected to begin only around end-2027 to mid-2028. - Current ZF utilisation is approximately 50–60%. - This creates a relatively long runway before the next major EV-related revenue contribution. - RACL therefore has time to build utilisation and capacity progressively rather than front-loading investment. EXPORT-LED BUSINESS MODEL - Exports account for approximately 66% of revenue. - Europe contributes around 59% of geographic revenue mix. - The high export exposure increases the importance of customer qualification, programme longevity and technical consistency. - Once qualified for long-life export programmes, repeatability and reliability can become meaningful competitive advantages. REPEATABILITY — THE REAL OPERATING MOAT - Management emphasises that the competitive advantage is not simply the ability to make samples. - The real challenge is consistently producing the same quality at large-scale volumes, where every individual part cannot be manually checked. - This creates a manufacturing moat based on process control, consistency and repeatability. - In other words, winning the sample is only the entry ticket; sustaining quality at scale is the real qualification. DISCIPLINED NEW-SEGMENT INVESTMENT - In aerospace, actuators, robotics and other emerging opportunities, management is deliberately avoiding premature capacity investment. - Management's approach is to invest only when there is sufficient confidence that the opportunity can become a profitable business. - This reduces the risk of building capacity ahead of customer demand. - Capital allocation is therefore being linked to commercial visibility rather than excitement around a new segment. FY27 CAPEX — REPLACEMENT + EXPANSION - FY27 capex is approximately ₹77.45 Cr. - Around ₹40 Cr is allocated toward heat-treatment replacement. - Around ₹35 Cr is allocated toward capacity expansion. - The new heat-treatment plant is expected to enter trials in January 2027. - Full commissioning is targeted by FY27-end. - The capex mix indicates that RACL is balancing maintenance/replacement investment with selective capacity creation. KEY TAKEAWAY - RACL's capex strategy is increasingly about matching capital deployment with the maturity of each customer programme. - BMW: October sign-off = technical qualification milestone. - Royal Enfield: movement toward 10,000 sets/month = commercial allocation milestone. - These are fundamentally different milestones and therefore require different capital-allocation responses. - The company's moat is increasingly based on repeatability at scale, customer qualification and long-term programme execution, rather than simply manufacturing capability. - With 66% export revenue + strong European exposure + sole-source TVS positioning + BMW qualification + ZF EV opportunity, RACL has multiple potential growth drivers, but management remains disciplined on capex. WHAT TO WATCH NEXT - BMW: final sign-off scheduled for 24 October. - Royal Enfield: monthly production sets and progress toward the ~10,000-set nomination. - Heat treatment: January 2027 trials and FY27-end commissioning. - ZF: progression toward electric-steering revenue beginning around end-2027 to mid-2028. - Raw material: clarification of the raw-material-cost bridge and its impact on margins. KEY RISKS - BMW final approval/sign-off could slip. - Domestic programmes could remain below nomination levels, delaying the case for additional capacity. - Depreciation could begin before corresponding programme revenue ramps up, creating near-term margin pressure. - Higher capex without sufficient utilisation could temporarily weigh on return on capital.

Jyoti CNC - ₹4848 Cr order book vs ₹1,950 Cr FY26 revenue. - Existing capacity is already almost fully utilized, while a new 10,000-machine capacity is coming online around Sep 2026. - Current capacity is 6,000 machines, so capacity would become 2.5x. - July bookings crossed 1,000 machines. - 25-30% revenue growth guidance with 25% EBITDA margin. - Expecting to book 8,000 machines out of the 10k by this FY

Be so positive that negative people don't want to be near you.

WOCKHARDT | FROM TURNAROUND TO A POTENTIAL NEW GROWTH STORY Wockhardt is becoming a very different pharma company. It has moved away from US generics and is increasingly focusing on: Novel Antibiotics + Insulin/Biologics + Existing Pharma Business FY26 already showed the change: Revenue +11% | EBITDA +51% | EBITDA Margin 18.6% The base business itself is getting healthier. THE BIG BET: NEW ANTIBIOTICS Wockhardt is developing new antibiotics for difficult bacterial infections. Why does this matter? Bacteria are increasingly becoming resistant to existing antibiotics, creating a growing need for newer treatments. This is where Wockhardt has built one of its biggest R&D opportunities. ZAYNICH — THE KEY ASSET Zaynich is designed for serious infections caused by drug-resistant Gram-negative bacteria. It has received US FDA and India approvals. So the investment question has changed: ❌ Will Zaynich get approved? ✅ How much can Zaynich sell? This is potentially Wockhardt's biggest new earnings driver. IT IS NOT ONLY ZAYNICH Wockhardt has several antibiotics targeting difficult bacterial infections: • Foviscu → difficult/ESBL Gram-negative infections • Miqnaf → bacterial pneumonia • Emrok / Emrok-O → difficult Gram-positive infections • Odrate → complicated urinary infections Foviscu has completed Phase III, while the other programmes are at different stages. So this is not simply a one-drug story. It is a portfolio of specialised antibiotics. SECOND ENGINE: INSULIN & BIOLOGICS Another major opportunity is Biologics / Insulin / Biosimilars. FY26 biotech revenue reached: ₹697 Cr | +27% Insulin production was doubled, while Glargine output was also substantially increased. The pipeline includes: • Insulin analogues • Biosimilars • GLP-1 products So Wockhardt potentially has a second growth engine alongside antibiotics. THE EXISTING BUSINESS MATTERS Wockhardt isn't simply waiting for Zaynich. Its existing businesses are also growing, particularly in the UK and emerging markets, while overall profitability has improved sharply. The result: EBITDA Margin: 18.6% A healthier existing business provides a stronger base from which to launch newer products. WHAT CAN CHANGE EARNINGS? Zaynich commercialisation → Growth in antibiotic portfolio → Insulin/biologics scale-up → Stronger cash generation → Lower debt The biggest monitorable by far: Can Zaynich turn approval into meaningful sales? WHAT CAN GO WRONG? The biggest risk now isn't simply R&D. It is execution. A drug can be approved but still take time to gain adoption. And antibiotics are meant to be used carefully, which can limit volumes. Other risks include: • Regulatory/quality risks • Pricing pressure • Slow commercial adoption • Difficulty converting profits into cash THE CRUX Wockhardt has moved from: US Generics Problems → Business Clean-up → Improving Profitability → Building New Antibiotics → Zaynich Approval Now comes the most important phase: Can Wockhardt convert its R&D into commercial success? Zaynich = Biggest Opportunity Insulin/Biologics = Second Engine Existing Business = The Base For investors, the equation is simple: Potential → Sales → Profits → Cash That's the Wockhardt story from here. No Recommendations, just sharing what I learnt in a simple way. Do your own studies. 📝

FOCUS on The GOOD THINGS, And The Good Things Will Follow.

How Sona Comstar Plans to Make Money in This Vertical ? Three Distinct Revenue Streams Novelic Acquistion was strategically important. Sona already had the body - while Novelic added an important piece of the sensing and perception layer. But capabilities alone don’t create shareholder value. The next question is much more important: How does Sona actually intend to monetise these capabilities? This is where the strategy becomes interesting. Sona is not looking at Robotics & Physical AI as one single business. Instead, it appears to be building three different ways of participating in the value chain starting with components, moving into perception and engineering, and eventually moving towards complete robotic systems. 1. Components & Subsystems: Start With What Sona Already Knows The most straightforward opportunity is to supply the critical hardware that robotic platforms need. This includes gearboxes, motors, actuators, AMR drive units, frameless motors and sensing components. In other words, Sona can sell the building blocks that allow a robot to move and interact with its environment. This is also where the strategic logic is strongest. Sona does not need to build an entirely new manufacturing ecosystem for robotics. The precision-engineering capabilities behind its existing automotive products—precision forging, gear grinding, motor manufacturing and high-accuracy assembly—can potentially be adapted to robotic applications. For example, a gearbox used in an EV drivetrain and a precision reducer used in a robotic joint may serve very different applications, but both demand extremely high manufacturing precision.A gearbox for an EV differential may operate at roughly 9:1 reduction, while a humanoid hip joint could require 100:1–160:1 reduction with near-zero backlash. The application changes, but the underlying disciplines—precision, repeatability, material quality and tight-tolerance manufacturing—remain highly transferable. This is the core of Sona’s hardware-convergence thesis: the engineering capability is not being built from scratch; it is being adapted to a new end market. Sona has already indicated its first order in this area: an advanced robotics subsystem for a robotics OEM, with SOP expected in H2 FY27. Management expects the business to have an EBITDA margin profile broadly similar to its existing precision-component business, at around 25–30%. So this first revenue stream is relatively easy to understand: take existing capabilities, adapt them for robotics, and sell them to robotic-platform companies. This is potentially the lowest-risk way for Sona to enter the market because it requires the least departure from its existing business model. But the more interesting opportunity begins when Sona moves beyond hardware. 2. Perception and ER&D: Monetising What Novelic Brings This is where the Novelic acquisition becomes directly relevant. A radar sensor by itself is only a piece of hardware. The real value comes from the ability to interpret the information that sensor generates. For a robot, that could mean understanding where an obstacle is, how far away it is, whether it is moving and how the robot should respond. This requires perception algorithms, embedded software and specialised engineering. Sona can potentially monetise these capabilities through ER&D (Engineering Research & Development) services and perception solutions for robotics companies. This is an attractive model because it is relatively asset-light. Instead of building another factory, Sona can leverage the engineering talent and technology platform it has developed through Novelic and work with customers that need specialised radar and perception capabilities. The first signs of commercialisation are already emerging, with an order for a radar perception stack for an AMR application, with SOP expected in Q2–Q3 FY27. If this business scales, its economics could also be quite different from manufacturing. This segment may have potential EBITDA margin profile of around 35–45%, reflecting the higher value of specialised engineering and software. But there is an important caveat. This is still ultimately a talent-driven business. The ability to scale will depend on whether Sona can attract and retain specialised engineers and convert project-based engineering work into a repeatable business. And then comes the most ambitious part of the strategy. 3. Full-Stack Platforms: Build the Robot The third revenue stream takes Sona much further away from its traditional business. Instead of supplying components to a robotics company, Sona is also exploring the possibility of building complete robotic platforms, initially focusing on AMRs for manufacturing and warehouses and cobots for industrial applications. This is where the different pieces of the strategy begin to come together. An AMR can combine Sona’s motor and drive capabilities with Novelic’s radar and perception technology, alongside motion-planning software, AI orchestration, fleet management and other software capabilities. Sona has already demonstrated an AMR prototype at CES 2026, and development of the production platform is continuing. The important point is not simply that Sona is building a robot. It is that Sona is trying to move from being a component supplier to becoming a systems player. That changes both the opportunity and the risk. A component business requires manufacturing excellence. A complete robotics platform requires manufacturing, software, AI, system integration, deployment, customer support and the ability to operate in a much more complex competitive environment. This segment is expected to have a lower initial EBITDA margin profile of around 15–22%. But the potential attraction is that a successful installed base could create additional revenue opportunities through software, fleet management, maintenance and services. What makes this architecture interesting is that these are not three completely separate bets. They build on each other. Sona can begin by supplying the hardware, add sensing and perception through Novelic, provide engineering and software capabilities, and eventually use those capabilities to build complete robotic systems. In simple terms, the ambition is to move slowly from component supplier → technology provider → systems player. That progression is strategically logical. But investors should also recognise that each step up the value chain increases the execution risk. Selling a gearbox is something Sona already knows how to do. Selling an autonomous robot to a factory is an entirely different challenge. So the strategy makes sense on paper. The next question is whether the market opportunity is large enough and whether Sona can capture enough of it to actually move the needle on the company’s overall financials.

GMM Pfaudler vs HLE Glascoat vs Standard Glass Lining , mapping the comarison and business profiles

As an investor, these are the actions I find worth tracking. Not just when a company sells more of what it already knows. But when it notices where the consumer is heading and gets there early. The interesting businesses are often hiding in plain sight. Sometimes, they start with something as ordinary as a packet of chips

Those are the questions that matter. If the answer to those questions is yes, this could become much more than another product in Parag's portfolio. It could become a high-frequency consumer business sitting on top of two powerful trends: protein and snacking. They have been been to scale the new age businesses of whey protein and Pride of Cows, so that gives some confidence.

That is why I am watching what Parag does with Avvatar Masala Chips. Protein chips in familiar flavours. 10g protein in a 30g pack. No - added sugar, palm oil or preservatives. On paper, it checks a lot of boxes. But I'm not convinced yet. Because launching a product is easy. Getting someone to buy it again is the real test. Will it taste good? Will people find the price reasonable? Will it be available everywhere? Will consumers actually make it part of their routine? And, eventually, can Parag make good money from it?

Then quick commerce entered the picture. Blinkit. Zepto. Faster discovery. Easier trial. And, importantly, repeat orders. The company went from being a small Shark Tank pitch to a business valued at much higher levels. Reports have put its valuation above ₹1,100 crore, while Aman Gupta's early investment has been reported to have grown from around ₹12 lakh to roughly ₹40 crore. The exact numbers are less important to me. The lesson is what matters. You don't always have to invent something new to build a big business. Sometimes you just have to make an existing product a little better. Better ingredients. Better positioning. Better distribution. Or simply a better reason for the customer to choose you.

People snack frequently. And when they find something they like, they don't buy it once. They come back for it. This reminds me of Let’s Try Foods. When the brand appeared on Shark Tank India in 2021, it looked like a small namkeen company entering a market already dominated by names like Haldiram’s. Ashneer Grover questioned whether it could really compete. But Let’s Try had one simple difference. It used 100% groundnut oil. No maida. No added preservatives. The product wasn't revolutionary. The thinking behind the product was. And that was enough to give consumers a reason to try something different.

Protein is no longer something only fitness enthusiasts talk about. It is slowly becoming part of everyone's food. Your daily meals. Your office snack. Your child's lunchbox. Your 4 PM craving. That’s where this gets interesting. Milk and ghee are huge categories for Parag. But snacking has something different going for it.